Low-Dose Decitabine for Patients With Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell Transplantation: A Pilot Therapeutic Study.

Low-DoseDecitabine for PatientsWith Thrombocytopenia Following Allogeneic Hematopoietic StemCell Transplantation: A Pilot Therapeutic Study Isolatedthrombocytopeniaafterhematopoietic stemcell transplantation (HSCT) isdefinedasconsistently lowplatelet counts after transplantation,withrecoveryofallotherperipheralblood cell lines.1 It represents a challenging clinical problem because itoften leads toan increasedriskof life-threateninghemorrhage, frequent requirementofplatelet transfusions, andextended hospital stays.2 Previous studies have demonstrated that decitabine, a hypomethylating agent, can increase platelet counts by enhancing platelet release and megakaryocyte maturation inmice.3 Herein, we report a pilot study showing efficacy of decitabine in patients with isolated thrombocytopenia post-HSCT.